173 related articles for article (PubMed ID: 11238476)
1. A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter.
Wesche MF; Tiel-V Buul MM; Lips P; Smits NJ; Wiersinga WM
J Clin Endocrinol Metab; 2001 Mar; 86(3):998-1005. PubMed ID: 11238476
[TBL] [Abstract][Full Text] [Related]
2. Effects on bone mineral density by treatment of benign nodular goiter with mildly suppressive doses of L-thyroxine in a cohort women study.
Appetecchia M
Horm Res; 2005; 64(6):293-8. PubMed ID: 16269872
[TBL] [Abstract][Full Text] [Related]
3. Determinants of longterm outcome of radioiodine therapy of sporadic non-toxic goitre.
Le Moli R; Wesche MF; Tiel-Van Buul MM; Wiersinga WM
Clin Endocrinol (Oxf); 1999 Jun; 50(6):783-9. PubMed ID: 10468951
[TBL] [Abstract][Full Text] [Related]
4. A slightly suppressive dose of L-thyroxine does not affect bone turnover and bone mineral density in pre- and postmenopausal women with nontoxic goitre.
De Rosa G; Testa A; Maussier ML; Callà C; Astazi P; Albanese C
Horm Metab Res; 1995 Nov; 27(11):503-7. PubMed ID: 8770627
[TBL] [Abstract][Full Text] [Related]
5. Effect of estrogen replacement therapy upon bone mineral density in thyroxine-treated postmenopausal women with a past history of thyrotoxicosis.
Franklyn JA; Betteridge J; Holder R; Sheppard MC
Thyroid; 1995 Oct; 5(5):359-63. PubMed ID: 8563472
[TBL] [Abstract][Full Text] [Related]
6. Prospective study of bone loss in pre- and post-menopausal women on L-thyroxine therapy for non-toxic goitre.
De Rosa G; Testa A; Giacomini D; Carrozza C; Astazi P; Caradonna P
Clin Endocrinol (Oxf); 1997 Nov; 47(5):529-35. PubMed ID: 9425392
[TBL] [Abstract][Full Text] [Related]
7. Bone mineral density in thyroxine treated females with or without a previous history of thyrotoxicosis.
Franklyn J; Betteridge J; Holder R; Daykin J; Lilley J; Sheppard M
Clin Endocrinol (Oxf); 1994 Oct; 41(4):425-32. PubMed ID: 7955453
[TBL] [Abstract][Full Text] [Related]
8. Stimulation with 0.3-mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign nontoxic nodular goiter: a prospective randomized double-blind trial.
Nielsen VE; Bonnema SJ; Boel-Jørgensen H; Grupe P; Hegedüs L
Arch Intern Med; 2006 Jul; 166(14):1476-82. PubMed ID: 16864757
[TBL] [Abstract][Full Text] [Related]
9. Thyroxine suppressive therapy decreases bone mineral density in post-menopausal women.
Kung AW; Lorentz T; Tam SC
Clin Endocrinol (Oxf); 1993 Nov; 39(5):535-40. PubMed ID: 8252741
[TBL] [Abstract][Full Text] [Related]
10. Effect of TSH-suppressive doses of levothyroxine on bone mineral density in Thai women.
Ongphiphadhanakul B; Puavilai G; Rajatanavin R
J Med Assoc Thai; 1996 Sep; 79(9):563-7. PubMed ID: 8996984
[TBL] [Abstract][Full Text] [Related]
11. The odyssey of nontoxic nodular goiter (NTNG) in Greece under suppression therapy, and after improvement of iodine deficiency.
Michalaki M; Kyriazopoulou V; Paraskevopoulou P; Vagenakis AG; Markou KB
Thyroid; 2008 Jun; 18(6):641-5. PubMed ID: 18578614
[TBL] [Abstract][Full Text] [Related]
12. Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women.
Marcocci C; Golia F; Bruno-Bossio G; Vignali E; Pinchera A
J Clin Endocrinol Metab; 1994 Apr; 78(4):818-23. PubMed ID: 8157704
[TBL] [Abstract][Full Text] [Related]
13. Postintervention serum TSH levels may be useful to differentiate patients who should undergo levothyroxine suppressive therapy after thyroid surgery for multinodular goiter in a region with moderate iodine deficiency.
Rotondi M; Amato G; Del Buono A; Mazziotti G; Manganella G; Biondi B; Sinisi AM; Santini L; Bellastella A; Carella C
Thyroid; 2000 Dec; 10(12):1081-5. PubMed ID: 11201853
[TBL] [Abstract][Full Text] [Related]
14. Levothyroxine suppressive therapy is partially effective in treating patients with benign, solid thyroid nodules and multinodular goiters.
Lima N; Knobel M; Cavaliere H; Sztejnsznajd C; Tomimori E; Medeiros-Neto G
Thyroid; 1997 Oct; 7(5):691-7. PubMed ID: 9349571
[TBL] [Abstract][Full Text] [Related]
15. Radioiodine therapy in patients with amiodarone-induced thyrotoxicosis (AIT).
Czarnywojtek A; Czepczynski R; Ruchala M; Wasko R; Zgorzalewicz-Stachowiak M; Szczepanek E; Zamyslowska H; Bartkowiak Z; Florek E; Sowinski J
Neuro Endocrinol Lett; 2009; 30(2):209-14. PubMed ID: 19675515
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma.
Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Biondi B; Iorio S; Giustina A; Amato G; Carella C
J Bone Miner Res; 2005 Mar; 20(3):480-6. PubMed ID: 15746993
[TBL] [Abstract][Full Text] [Related]
17. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine.
Marcocci C; Golia F; Vignali E; Pinchera A
J Bone Miner Res; 1997 Jan; 12(1):72-7. PubMed ID: 9240728
[TBL] [Abstract][Full Text] [Related]
18. The effect of suppressive thyroxine therapy in nodular goiter in postmenopausal women and 2 year's bone mineral density change.
Chen CY; Chen ST; Huang BY; Hwang JS; Lin JD; Liu FH
Endocr J; 2018 Nov; 65(11):1101-1109. PubMed ID: 30158361
[TBL] [Abstract][Full Text] [Related]
19. Possible limited bone loss with suppressive thyroxine therapy is unlikely to have clinical relevance.
Müller CG; Bayley TA; Harrison JE; Tsang R
Thyroid; 1995 Apr; 5(2):81-7. PubMed ID: 7647577
[TBL] [Abstract][Full Text] [Related]
20. Bone mineral density in premenopausal women receiving levothyroxine suppressive therapy.
Nuzzo V; Lupoli G; Esposito Del Puente A; Rampone E; Carpinelli A; Del Puente AE; Oriente P
Gynecol Endocrinol; 1998 Oct; 12(5):333-7. PubMed ID: 9859026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]